Skip to main content
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. — Investor Relations & Filings

Ticker · NAUT ISIN · US63909J1088 US Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2021-04-20 Regulatory Filings
Country US United States of America
Listing US NAUT

About Nautilus Biotechnology, Inc.

https://www.nautilus.bio/

Nautilus Biotechnology, Inc. is a life sciences company developing a platform to revolutionize proteome analysis. The company's Proteome Analysis Platform is designed to quantify proteins at the single-molecule level, leveraging a proprietary method called Iterative Mapping. This technology aims to provide high-resolution views of billions of individual protein molecules and their modifications (proteoforms). The platform is being developed with two key modalities: broadscale proteomic analysis for comprehensive proteome exploration and targeted proteoform analysis for in-depth examination of protein variants. The intended applications include accelerating drug target identification, discovering more effective biomarkers, and enabling foundational biological research by making advanced proteomics more accessible to the scientific community.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-04-20 English
S-4/A
M&A Activity Classification · 95% confidence The document is an Amendment No. 1 to a Form S-4 Registration Statement filed with the SEC. It includes exhibits related to a business combination, such as agreements, corporate governance documents, employment letters, and consents. The Form S-4 is a registration statement used for securities issued in business combinations and exchange offers. The document is not a financial report like an Annual Report or Interim Report, nor is it a simple announcement or proxy solicitation. It is a regulatory filing related to a merger transaction, specifically a registration statement amendment for a business combination. Therefore, the most appropriate classification is 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids, including Form S-4 filings.
2021-04-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 7, 2021, by ARYA Sciences Acquisition Corp III. It includes a Regulation FD Disclosure with presentation materials related to a business combination with Nautilus Biotechnology, Inc. The document references a Registration Statement on Form S-4 and a forthcoming definitive proxy statement/prospectus for shareholder voting on the business combination. The content focuses on disclosure and solicitation materials related to the merger transaction, including forward-looking statements and disclaimers. There are no financial statements or detailed financial analysis present, nor is this a full annual or quarterly report. The document is primarily a regulatory filing to announce and provide information about the business combination and related proxy solicitation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-04-07 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ARYA Sciences Acquisition Corp III. It discusses a business combination with Nautilus Biotechnology, including presentation materials related to employee stock options treatment. The filing references a Registration Statement on Form S-4 and proxy statements related to the business combination. The document is primarily a regulatory disclosure about the business combination and related proxy solicitation, not a full financial report or earnings release. It includes forward-looking statements and disclaimers typical of merger-related communications. The document is not a full annual or quarterly report, audit report, or earnings release. It is a regulatory filing providing information about the business combination and related proxy materials, consistent with the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings that do not fit other categories.
2021-04-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text includes a press release about the appointment of a General Counsel and extensive information about a proposed business combination (merger) between ARYA Sciences Acquisition Corp III and Nautilus Biotechnology, including references to a Registration Statement on Form S-4 and proxy statements. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is primarily a regulatory filing disclosing material corporate events and providing information about the merger process and related proxy solicitation. The document length is over 10,000 characters and contains detailed disclosures, but it is not a standalone financial report. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-04-06 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content includes a press release about the appointment of a new General Counsel and information about a proposed business combination, including references to a Registration Statement on Form S-4 and a proxy statement to be mailed to shareholders. There are no financial statements or detailed financial data presented in this document. The document primarily serves as a regulatory filing to disclose material corporate events and forward-looking statements. It does not contain an annual report, earnings release, or detailed management discussion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2021-04-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.